inhibits platelet responses 5 ); albumin probably to bind released arachidonate and its products and to decrease adhesion of platelets to foreign surfaces; apyrase to destroy released ADP and avert refractoriness; 8 and calcium ions. 5
Platelet Stimuli
Physiologic stimuli that can activate platelets both in vivo and in vitro are amazingly diverse. Some are paniculate, such as collagen. Others are proteolytic enzymes, such as thrombin or trypsin, and still others are low molecular weight compounds such as ADP, serotonin, or epinephrine. Each of these agents has specific receptors on the outer surface of the plasma membrane, discussion of which is beyond the scope of this review.
Other stimuli arise under pathologic conditions. Among these are antigen-antibody complexes or aggregated gamma globulin that react with an Fc receptor on human platelets and a complement receptor on rabbit platelets. 7 ' 8 Platelet-activating factor (PAF)-acether (1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) is produced by activated leukocytes and stimulates platelets at low concentrations. 9 ' 10 Several foreign substances have been very helpful in elucidating the mechanisms for platelet activation. Among these are phorbol myristate acetate (PMA, also known as tetradecanoyl phorbol acetate or TPA), an irritant and tumor promoter found in croton oil, and the calcium ionophores, A 23187 and ionomycin. They will be discussed later. ATP  CIE  CTC  DAG  DTT  EDTA  cyclic GMP  GP  IP3  NSAI  OAG  PA  PAF  PC  PE  PG  PI  PIP  PIP2  PMA  TMB-6 TPA TxA, Abbreviations adenosine 5'-diphosphate 3', 5'-adenoslne monophosphate adenosine triphosphate crossed immunoelectrophoresis chlorotetracycllne dlacylglycerof drthiothrertol ettiytenediaminetetraacetic add 3', 5'-guanosine phosphate glycoprotelns inosftol-1,4,5-triphosphate nonsteroidal anti-inflammatory 1 -oleoyl-2-acetyl-glycerol phosphatldlc acid platelet-activating factor phosphaticlylcholirte phosphatidylethanolamine prostaglandin phosphatktylinoslto) phosphatkrytinositoM-phosphate phosphatidy1inosrtol-4,5-bisphosphate phorbol myristate acetate 6-(N,N-diethytamlno)octyl-3,4,5-trimethoxybenzoate tetradecanoyl phorbol acetate thromboxane Aj
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Platelet Responses
It is remarkable that the responses to the wide variety of stimuli that affect platelets usually follow essentially the same pattern: platelets change their shape, then become sticky so that they aggregate if brought into contact by stirring, and finally secrete the contents of their three types of granules -dense bodies, alpha granules, and lysosomes. Secretion may be triggered by products of released arachidonic acid, but these compounds are not required Zucker and Nachmias 3 with strong stimuli such as thrombin. With that stimulus, secretion is initiated in 1 to 2 seconds and is essentially complete in a few minutes. 11 Shape change and aggregation can be studied with a platelet aggregometer, which records transmission of light through a stirred platelet suspension (Figure 1 ). With critical agonist concentrations, secretion is indicated by a second wave of aggregation. Secretion of adenosine triphosphate (ATP) or of Ca 2+ can be recorded directly with a lumi-aggregometer 12 (Figure 1 
Shape Change
Most stimuli cause a change in shape ( Figure 2 ). This change involves first the formation of very fine (0.1 fxm diameter) pseudopodia (i.e., filopodia) from the rim of the disc, followed by a general "rounding up" of the platelet so that it becomes a spiny sphere, often with much broader pseudopodia. 14 With epinephrine, the discoid shape is maintained. The asymmetric shape of discoid platelets accounts for the "swirl" that is noted by eye when suspensions are shaken, and for the stirring-dependent oscillation seen in many aggregometer tracings. Shape change is seen in an aggregometer tracing as a decrease in light transmission and loss of the oscillation. If aggregation follows, this decrease is succeeded by increased light transmission ( Figure 1) .
The fine filopodia are seen to be formed of tight bundles of actin filaments when they are demembranated with nonionic detergent and examined by negative staining. When decorated with heavy B Figure 2 . Scanning electron micrographs of resting discoidal platelets (A) and platelets after activation with ADP (B). Note the thin filopodial extensions and irregular shape of the activated platelets, x 5000. meromyosin, they develop the well known "arrowheads" that point toward the cell body ( Figure 3 ). This finding suggests that the filopodia are probably not "slid out" from the platelet by interacting with myosin, which would require the opposite polarity. 15 In support of this conclusion, the'cytoplasm of purely discoid platelets does not appear to be replete with fully formed, long microfilaments, but rather to con-tain short fragments of such filaments and amorphous ground cytoplasm. 16 ' 17 The amorphous component could be composed of actin complexed with profilin, a protein present in platelets in amounts sufficient to complex part, but not all, of the actin (see Table 1J . 18 -50 However, some investigators, using different methods, 49 . x have found that "resting" platelets contain at least some long microfilaments. . Cytoskeleton of partially spread platelets after lysis with 1% Triton X-100 and negative staining with 2% uranyl acetate. Note the network of thin filaments, the bundles of parallel filaments (FB) and the remnant of the microtubulecoil(MT). Bar = 1 ^m. x 10,500. The Inset shows thin filaments decorated with heavy meromyosin S-1. Note that the "arrowheads" point toward the cell body, x 70,000. (Reprinted from Blood 1977;50:42, with permission from the publisher and authors.) Interacts with myosin to produce tension. Also forms bundles with actin-binding protein, and alpha-actinin. F-form binds tropomyosin, gelsolin, and 235 K. Present in filopodia as bundles, in body of platelet as nets. G-form binds profilin.
MT
W-FB
When phosphorylated on LCI by myosin light chain kinase, 20, 23-29 interacts with actin to produce tension. Also assembles to make bipolar filaments when phosphorylated. Present in pseudopodia and in body of platelet. Absent from 0.1 nM filopodia.
Crosslinks F-actin to nets or bundles. Present in filopodia, is phosphorylated, which may alter binding to actin.
Crosslinks actin, which is decreased by Ca 2+ . Promotes actin polymerization. Binding to actin is reduced by calcium. Not an intrinsic membrane protein. In filopodia and ruffles.
Binds to F-actin and stabilizes the filament. Competes with filamin (like APB) for binding. Present in filopodia. Sequenced, 247 residues.
Restricts length of F-actin filament
Binds to G-actin and stabilizes it. About 55% of actin in platelets present as profilactin.
Transfers P from ATP to myosin LCI to make actin-activated ATPase. Activated by Ca 2+ -calmodulin. Phosphorylated by cAMP-dependent kinase which decreases its activity.
Binds to F-actin at the barbed end; "caps" the actin filament in presence of calcium.
Heterodimer. Polymerizes to form microtubules; assembles into coil in intact platelets. Disassembles and reforms into straight segments in pseudopodia or into larger coils after chilling and rewarming. May be associated with high MW protein. There is still considerable uncertainty as to whether the short fragments of microfilaments in unactivated platelets are "capped" by molecules that inhibit long filament growth. A 90 K gelsolin molecule, for example, has this property (Table 1)/ 2 but under some conditions it can also increase the rate of actin polymerization.* 3 Actin is not the only component of the filopodia; immunofluorescence studies 27 indicate that tropomyosin, alpha-actinin, and actin-binding protein are also present. A periodicity that could be produced by staggered tropomyosin (17 nm) has been seen occasionally in negatively stained filopodia. 15 The second step in shape change, the change from a disc into an irregular sphere, is correlated with the phosphorylation of platelet myosin, specifically the 20,000 dalton light chain. 51 When platelets spread on surfaces, they first put out short filopodia and then the cytoplasm fills the space between them with what appears to be a network of actin filaments ( Figure 3 ). M Actin assembly, actin-myosin interaction, and effects on microfilament length via gelsolin probably all occur during spreading, but biochemical studies to correlate with the morphologic observations are difficult to perform.
Shape change with or without secretion causes the microtubule bundle that lies beneath the rim of the disk to become centralized and surround the platelet granules, which are consequently concentrated toward the center of the platelet. 53 The diameter of the microtubule ring decreases 30% to 40% after thrombin or ADP stimulation. Centralization of the granules occurs in platelets treated with taxol, a drug that stabilizes microtubules, which indicates that depolymerization of the microtubules is not necessary. 47 However, granule centralization is prevented by cytochalasin B, which can cap actin filaments. 54 Thus the idea that actin-myosin interaction causes granule centralization and possibly contraction of the microtubule ring is attractive. 47 Granule centralization does not occur when platelets are activated with phorbol esters (e.g., PMA), which activate protein kinase C (see below). 54 With isolated components, this kinase phosphorylates myosin light chain, but at a different site than does the light chain kinase. 55 This may explain the difference in granule centralization caused by thrombin and phorbol esters. However, in whole platelets, PMA causes some phosphorylation at the light chain kinase site. 55 Aggregation ADP, thrombin, serotonin, vasopressin, and epinephrine initiate aggregation within a few seconds ( Figure 1 ). Fluid-phase calcium or magnesium is necessary for aggregation. 5657 In addition, fibrinogen is also required. With ADP or epinephrine, this protein must be present in the suspension medium, whereas with thrombin or collagen it is secreted from the alpha granules. 58 When platelets are stimulated with ADP, specific fibrinogen binding sites appear on the platelet surface. The subject has been reviewed recently. 59 The C-terminal dodecapeptide of the fibrinogen gamma chain is the major binding site and, while the peptide alone cannot cause aggregation of ADP-stimulated platelets, albumin to which several of the peptides have been coupled can do so. 60 This observation reinforces the view that aggregation results when the dimeric fibrinogen molecule binds to two platelets. ADP-induced fibrinogen binding or aggregation induced in the absence of secretion is readily reversed if EDTA is added or ADP is enzymatically removed soon after aggregation has occurred. Thus, continued occupancy of the ADP receptor is necessary to maintain "availability" of the fibrinogen binding sites.
A complex of two of the glycoproteins (GP) on the platelet surface, GP lib and Ilia, appears to constitute the fibrinogen receptor. This conclusion is based on the following findings: 1) Platelets from patients with the congenital disorder thrombasthenia cannot aggregate or bind fibrinogen and have little or no measurable GP lib and Ilia on their plasma membrane. 5961 2) Platelets have about 40,000 molecules of GP Mb and Ilia on their surface, the same as the maximum number of fibrinogen molecules they can bind. 62 3) Isolated GP Mb and Ilia adsorbed to plastic bind fibrinogen in the presence of calcium. 63 4) The rocket formed by GP Mb and Ilia in crossed immunoelectrophoresis can bind fibrinogen. 64 5) Monoclonal antibodies that react with the GP llb-llla complex inhibit fibrinogen binding and ADP-induced platelet aggregation. 62 6) A photoactivatable derivation of fibrinogen becomes crosslinked to GP Ilia on ADP-activated platelets. 65 External calcium or magnesium is not necessary for inducing the fibrinogen receptor. 66 Formation of the heterodimer complex of GP lib and Ilia in vitro specifically requires calcium. If the isolated glycoproteins are separated by adding a chelating agent, they cannot bind fibrinogen in vitro. 6364 The mechanisms of induction of the fibrinogen receptor are not clearly understood. Inasmuch as the monoclonal antibodies that recognize the heterodimer complex of the GP Mb-Ilia bind equally well to the surface of unstimulated and stimulated platelets, 62 some change other than formation of the complex must be responsible for promoting fibrinogen binding. Isolated membranes bind only about 1% of the amount of fibrinogen that would be expected. 67 ' M ADP does not increase the binding of fibrinogen to the membranes, 6768 yet binding seems to depend upon the GP Mb-Mla complex since a much smaller amount is bound to membranes from thrombasthenic platelets. 68 With isolated membranes, magnesium cannot support fibrinogen binding unless about 1 /i,M Ca 2+ is present. 68 This amount may represent the Ca 2+ that is released into the cytoplasm of stimulated platelets (see below), which causes some change in GP lib and/or Ilia that is transmitted through the membrane and permits the platelets to bind fibrinogen. Dithiothreitol (DTT) causes platelets to bind fibrinogen and aggregate, 69 ' 70 presumably by cleaving disulfide bonds in the platelet. GP Mb and/or Ilia are implicated, since thrombasthenic platelets fail to aggregate, 70 but the mechanism is obscure, since DTT-induced aggregation is not inhibited by elevating cyclic adenosine monophosphate (AMP). 69 An ingenious alternative theory to explain the development of fibrinogen binding sites after platelet activation is that GP llb-llla are simply hidden by other surface molecules in unstimulated platelets. 71 When platelets spread, their surface area increases enough to permit the fibrinogen to reach GP llb-llla. Possibly, shape change has a similar effect.
Fibrinogen binding is necessary but not sufficient for aggregation. Membrane flow also appears to be required, as aggregation fails to occur despite the presence of bound fibrinogen when studies are carried out in the cold, or using platelets fixed with formalin after stimulation with ADP. 66 Membrane flow is responsible for the entry of macromolecules into the open canalicular system as well, whereas a different, energy-dependent process is involved in phagocytosis of particles such as latex beads. 72 Electron microscopy shows that fibrinogen and GP lib and Ilia are clustered on the surface of thrombin-aggregated platelets. 73 Activated but nonaggregated (e.g., unstirred) platelets have not been studied. Such clustering may be necessary for the formation of the relatively large aggregates (over seven platelets) detected in an aggregometer. Small aggregates develop earlier and are more difficult to inhibit; 74 their formation may not be associated with receptor clustering.
Platelet stimulation by epinephrine differs from that caused by ADP and thrombin because it is not associated with change in platelet shape. According to some investigators, 75 but not others, 76 excitation is accompanied by influx of calcium ions. Binding fibrinogen is thought to occur independently of plateletderived ADP by some, but not all, investigators. 59 Fibrinogen secreted from the alpha granules can mediate thrombin-and collagen-induced aggregation. GP Mb and Ilia in these granules are presumably exteriorized when secretion occurs and constitute the site to which the granule fibrinogen binds. 77 Under these conditions, aggregation is reinforced by a lectin-like association between platelet-bound fibrinogen and thrombospondin, a large protein that is also secreted from the alpha granules and remains attached to the platelets. 78 Other bonds, so far poorly understood, may also bind the platelets together. 79 As a result, aggregation associated with secretion is not readily reversed.
The 235 K protein and actin binding protein undergo proteolysis, although to different degrees, starting 30 seconds after thrombin-induced aggregation. 80 Thrombin-induced activation without aggregation was not effective. 8081 Proteolysis is due to the calcium-and thiol-dependent neutral protease that is found in the platelet cytoplasm.
Adhesion
There are several mechanisms for platelet adhesion. Platelet adhesion to glass is mediated by fibrinogen 82 and depends on GP llb-llla, since thrombasthenic platelets adhere poorly. However, for reasons that are unclear, normal platelets adhere to fibrinogen-coated surfaces without requiring stimulation with ADP. 83 Platelets probably adhere to purified collagen via specific receptors. 84 Platelets adhere to the vascular subendothelium but there is disagreement concerning the active component. At high shear rates, von Willebrand factor is necessary for this adhesion. 85 Adhesion to this surface is associated with loss of granules (i.e., secretion), which is not inhibited by nonsteroidal anti-inflammatory (NSAI) agents. 88 
Secretion
The contents of the three types of secretory granules in platelets are listed in Table 2 . If secretion is not recorded (see above), it can be monitored in vitro by measuring the secreted products in the medium after arresting secretion by adding EDTA and chilling the sample or by adding formaldehyde 87 before centrifugation. Platelets whose dense granules have taken up 14 C-serotonin can be used to monitor secretion by measuring release of radioactivity. 88 '" Commercially available radioimmunoassays for betathromboglobulin and platelet factor 4 permit detection of alpha granule secretion. Since very little of these proteins is contained in carefully collected plasma, their presence suggests that platelets have been activated in vivo. 90 One pathway for secretion involves formation of the prostanoid thromboxane Aj (TxAj). TxA, is formed from the 20-carbon polyunsaturated arachidonic acid (20:4) ( Figure 4 ), which is cleaved from phospholipids and released during platelet activation (see later). 91 Addition of arachidonate, endoperoxides, or TxAj to platelet suspensions induces aggregation and secretion. The responses to arachidonate, ADP, and epinephrine can be blocked by use of NSAI agents that inhibit cyclooxygenase ( Figure 1 ); aspirin inhibits this enzyme irreversibly. 86 Dazoxiben, an imidazole derivative that inhibits thromboxane synthetase but not the synthesis of endoperoxides, has a complex effect on arachidonate-induced platelet aggregation, because PGE 2 , a potentiator, and PGD 2 , an inhibitor, are formed. 92 Compounds of this type may prove more useful than NSAI in pre- venting thrombosis since they do not prevent the blood vessel wall from forming the platelet inhibitor prostaglandin l 2 (PGI 2 ) from endoperoxides. 93 Thrombin has been widely used to study secretion as it is the most potent physiologic stimulus, and secretion can occur in nonaggregated suspensions. Alpha granules respond at a lower thrombin concentration than dense granules. 58 Both responses are called Release I. Secretion from lysosomes, socalled Release II, requires a higher thrombin concentration and continued receptor occupancy by thrombin, which is not necessary for Release I. 94 NSAI agents inhibit secretion only at very low thrombin concentrations (i.e., less than 0.04 U/ml). With higher concentrations, secretion is associated with stimulation of protein kinase C (see below), which is unrelated to formation of TxA,. PAF is not involved in thrombin-induced secretion. 9 Epinephrine and ADP cause Release I but not Release 11. Secretion by these agonists is highly temperature-dependent, occurring at 37° C but not at room temperature, 88 and requires formation of products of arachidonic acid, which are thus abolished by NSAI agents. Secretion occurs only in association with aggregation, 9596 perhaps because the close platelet contact prevents the low concentration of released arachidonate products from diffusing away from the platelet surface (suggested by Dr. William Lands). ADP-induced secretion takes place only in a medium low in Ca 2+ , such as citrated plasma, 9798 which makes its physiologic role doubtful.
When secretion and aggregation are induced with critical concentrations of epinephrine or ADP, secretion is associated with a second wave of aggregation. With lower concentrations of the agonists, secretion is not triggered. With higher concentrations of ADP, only one phase of aggregation is seen, but secretion can be readily detected by monitoring secreted products, whereas with epinephrine, primary aggregation is always weak and secretion delayed ( Figure 1) .
Several platelet products probably implement secondary aggregation although investigators do not agree on their relative importance. ADP secreted from the dense granules plays a part, 99 but endoperoxides and TXAj also have direct effects. 100 ' 101 Presumably, too, these substances potentiate each others' effects. 102 Since ADP is secreted and can itself induce secretion if aggregation occurs, it provides a strong feedback loop in studies with citrated plateletrich plasma.
Unlike thrombin, ADP, and epinephrine, the aggregation induced in an aggregometer by low concentrations of collagen particles is abolished by NSAI agents and is entirely dependent upon the liberation of arachidonate and formation of its products. Thus, collagen does not cause "primary" aggregation. With high concentrations of collagen, adhesion of several platelets to one particle presumably causes the aggregation, and NSAI agents are ineffective. 96103 The process of exocytosis of dense granules has eluded visualization by electron microscopy, but studies using immunufluorescence 104 or a combination of immunocytochemistry with transmission electron microscopy 105 have clarified the mechanism for the release of alpha granules. Thrombin causes the alpha granules to fuse with each other and with elements of the surface-connected canalicular system so that large vacuoles form in the center of the cell. Interestingly, such large vacuoles have often been observed in routine electron micrographs of secreting platelets. The vacuoles seem to connect to the extracellular space by a widened region in the necks of the surface-connected system. By immunocytochemistry, 105 fibrinogen, beta-thromboglobulin, and platelet factor 4 were shown to be located both in the large vacuoles and along the plasma membrane, suggesting that at least some of the secreted material remained bound to the outer membrane, an observation that agrees with studies using other methods.
Structural Changes and the "Cytoskeleton"
Platelet responses are mediated by alterations in cytoplasmic structural proteins. Table 1 summarizes the known and suspected structural proteins and related enzymes. Besides actin, which forms 10% to 15% of platelet protein, and myosin, these proteins fall into four classes: those that complex G-actin (profilin); those that crosslink actin (actin binding protein and alpha-actinin); those that stabilize the filament (tropomyosin); and those that cap filaments (90 K protein, probably the same as gelsolin) or restrict the length of actin (235 K protein). 22 Other proteins that interact with the structural proteins are: myosin light chain kinase (which may bind to actin or myosin); calcium-activated protease, which can break down actin-binding protein and 235 K protein; and calmodulin, which complexes with the kinase and possibly with other proteins.
The structural proteins are often referred to as the "cytoskeleton." The term derives from the finding that when cells, including platelets, are treated with nonionic detergents such as Triton X-100, the membranes become soluble and, together with soluble proteins and small molecules, are washed away, leaving an insoluble residue of structural proteins that retains the shape of the cell, and, unlike F-actin, sediments quickly at less than 20,000 g.
"Cytoskeleton" is an operational term, since its composition varies with temperature, ionic strength, pH, presence of chelators, etc. For example, myosin appears in the cytoskeleton of resting platelets if EDTA is used instead of EGTA. 30 ' 106 Alpha-actinin appears if the cytoskeletons are formed at 0 to 5° C at pH 6.B, 34 -36 but not if they are formed at room temperature at pH 7.4, 49 probably because alphaactinin has greater affinity for actin in the cold. Tritoninsoluble residues may be useful for the purification of components such as actin-binding protein. 21 Despite these in vitro differences, there is general agreement that the cytoskeleton of resting plate-lets contains actin. Actin-binding protein is usually but not always 107 detected on gels. After activation with thrombin, arachidonate, or ionophore, more actin is present, and the myosin is strikingly increased. 30333451107 - 110 The DNase assay demonstrates a major increase in the proportion of actin in the F-form after thrombin. 106 ' 111 Formation of a Triton X-100-insoluble "contractile gel," rich in actin and myosin, and a Triton-insoluble "pseudopodal gel," rich in actin and actin-binding protein, can be differentiated. While both are produced by stimulation with thrombin, only the latter is inhibited by cytochalasin D or formed by stimulation with PMA. 54 It should be noted that cytoskeletons are collected at low gforces which do not sediment F-actin that is not bound or cross-linked. 49 The increased presence of myosin in the cytoskeleton after stimulation with thrombin, collagen, A23187, or ADP is correlated with phosphorylation of the 20,000 dalton light chain of myosin. 2851 ' 109 Both changes can be reversed by elevating cyclic AMP. 107 -110 The increase of myosin probably results from the ability of phosphorylated myosin to form filaments and interact with actin. 25 ' ^4 1 Myosin phosphorylation is due primarily to the light chain kinase, which is calcium-and calmodulin-dependent. 2324 Thus, an increase in [Ca 2+ ]| would be expected to activate myosin. It is still unclear whether the troponin system plays any role, but troponin-l has recently been found in platelets. 112 Myosin phosphorylation caused by thrombin precedes secretion. 28 It is related to tension production, since actomyosin threads from platelets can exert as much tension as muscle actomyosin only if myosin has been phosphorylated. 20 Phosphorylation of the light chain and the extent of shape change are closely correlated, 51 suggesting that myosin plays a role in this earliest sign of platelet activation. Interestingly, dephosphorylation occurs soon thereafter, before the platelets return to their original shape.
Actin-binding protein can also be phosphorylated several fold when platelets are stimulated with thrombin 113 or arachidonate. 107 Phosphorylation is paradoxically also increased by addition of PGI 2 or dibutyryl cyclic AMP; 107 perhaps different sites are involved. Surprisingly, dephosphorylation occurs soon after addition of thrombin only if the platelets have been allowed to aggregate. 113 Purified phosphorylated actin-binding protein crosslinks actin. 114 Because platelets exert tension on surfaces 115 or during clot retraction, there must be direct connections between the plasma membrane and structural proteins capable of exerting tension. A number of investigators have reported that membrane proteins or components that may be bound to the membrane after activation are then found in the Triton-insoluble residue. To determine that this has physiologic relevance, it is important to show relative enrichment of the new components in the cytoskeleton over those present in resting platelets; specific association must also be demonstrated. This is particularly difficult be-cause the cytoskeleton consists of fibrous proteins that may bind components nonspecifically, and actin is notoriously "sticky." GP Mb and Ilia were associated only with cytoskeletons made from platelets that had been activated with thrombin or ADP and then aggregated, but not with those from platelets activated without aggregation. 106 ' 116 ' 117 The association may be nonspecific, because lipid phosphorus and fragments of membrane were found in cytoskeletons formed after aggregation. 106 In contrast, concanavalin A causes an association of surface glycoproteins with the cytoskeleton, not by precipitation, but as a result of increased interaction. 106118 It did not cause platelet aggregation or increased inclusion of lipid in the cytoskeleton. 106 Cytoskeletons from thrombin-treated platelets showed selective enrichment of two of the major phospholipids and glycolipids. 119 Very recently, it was reported 120 that 24% to 30% of the platelet GP llb-llla complex was associated with the Triton-insoluble cytoskeletal core of platelets that were aggregated with arachidonic acid or PMA. The addition of cytochalasin E prevented this association, as well as the formation of a pseudopodal core, but it did not prevent aggregation or alter the amount of phospholipid in the cytoskeleton. GP llb-llla was also not associated with the core when aggregation was prevented by adding fibrinogen fragment D, which is monovalent and therefore binds to the fibrinogen receptors without inducing aggregation. Thus, firm binding of GP llb-llla to the cytoskeletal core depends on both the formation of a pseudoposal gel and on aggregation itself, rather than on receptor occupancy.
Although the cytoskeletons of unstimulated platelets did not contain GP lib or GP Ilia, a glycoprotein of M r 158,000 (reduced; M, 170,000 unreduced) was detected by 125 l-labeling of whole platelets 106 or by incubating gels with 125 l-labeled wheat germ agglutinin. 117 Crossed immunoelectrophoresis (CIE) showed that Triton X-100 exfracts of platelets made in the presence of leupeptin contain a complex of GP Ib with another component. 121 The Triton-insoluble cytoskeletons also contained GP Ib. If extraction was carried out in the presence of calcium without leupeptin, GP Ib was not found in the cytoskeleton, and had increased mobility in CIE studies of the soluble extracts. Under these conditions, actin-binding protein was proteolyzed by the calcium-dependent neutral protease, although GP Ib was not. The data were interpreted to mean that GP Ib may bind to the small actin bundles produced by actin-binding protein, but could also indicate that GP Ib binds directly to actinbinding protein. The latter view was supported by the observation 122 that actin-binding protein and GP Ib copurify from an affinity column carrying a monoclonal antibody to GP Ib. Thus, the association of GP Ib to actin-binding protein may provide a transmembrane link through which tension can be transmitted. It is of interest that GP Ib can be phosphorylated 121 as well as actin-binding protein. 107113 Several alpha-granule proteins associate with the cytoskeleton of thrombin-activated platelets. These include activated platelet factor V 123 and endogenous 124 or labeled exogenous 124 ' 12S fibronectin. It is surprising that cytoskeletons from thrombin-treated thrombasthenic platelets contained a normal amount of fibronectin, 124 although such platelets do not express this protein on their surface after thrombin stimulation. 126 Fibrin monomers also associate with the thrombin-elicited cytoskeleton. 127 The experiments were carried out in the presence of the peptide Gly-Pro-Arg-Pro, which inhibits fibrin polymerization, and thus prevents polymerized fibrin from sedimenting when the cytoskeleton is removed by centrifugation. The cytoskeletons of thrombin-treated thrombasthenic platelets bound much less fibrin monomer, which suggests that GP llb-llla was involved. The result is surprising, since others 106 ' 116 have not found these glycoproteins to be associated with the thrombin-induced cytoskeleton unless the platelets had aggregated. It is possible that the platelets had aggregated in these experiments; the cytoskeletons were prepared with a high concentration of thrombin (1 U/ml) in the presence of calcium ions. It is also possible that association of GP llb-llla with the cytoskeleton was prevented by the chelating agents that were used during preparation of the cytoskeleton in all other studies.
Transductlon of the Stimulus
None of the physiologic agonists can penetrate the plasma membrane of the platelet. There must therefore be some mechanism(s) by which the stimulus is conveyed across the membrane to trigger internal changes such as the organization of platelet actin into microfibrils, or secretion from the granules.
It is clear that a wide variety of agonists (actually agonist-receptor complexes) cause similar responses in platelets. Platelet shape change, aggregation, Release I, and Release II are thought to result from increasing concentrations of one or more intracellular transmitters. The responses appear to be sequential. However, this is not because each depends on the former one but because of the order of their dependence on transmitter concentration. Increased [Ca 2+ ], is an important transmitter, but newly produced diacylglycerol is also important.
Role of Sodium and pH
Removal of extracellular sodium inhibits the ability of platelets to secrete in response to stimulation with epinephrine, ADP, and low (less than 0.04 U/ml) concentrations of thrombin. Aggregation is inhibited to the same extent as when cyclooxygenase is inhibited. Thus, it is inferred that sodium deprivation may prevent activation of the cyclooxygenase. 128 Low concentrations of thrombin also increase the ^Na content of the platelets about threefold, accompanied by an increase in the fluorescence of 3,3'-dipropylthiodicarbocyanine, which represents depolariza-tion of the platelet membrane. The extent of the depolarization depends on [Na + ] 0 , with 20% effect remaining at 29 mM Na + . Both changes are prevented and even reversed by a fast-acting amiloride analogue, L591-605, which blocks the entry of Na+. The interpretation is that the entry of sodium causes the depolarization produced by low concentrations of thrombin. 129 Megakaryocytes exhibit a sodiumdependent change in membrane potential after ADP or thrombin (1 U/ml), which is prevented by sodium channel blockers and which is correlated with cell spreading. 130 Work with appropriate dyes indicates that, in addition to causing membrane depolarization, thrombin causes the internal platelet pH ro rise approximately 0.3 units. 131 Partial depolarization of the membrane resulting from increased extracellular potassium reportedly increases the response to ADP. 132 ADP increases sodium entry and causes platelet shape change, but when internal sodium was increased by blocking the sodium pump with ouabain, shape change did not occur, 133 which suggests that an increase in [Na+J, is not sufficient. If sodium were acting via sodium-proton exchange rather than by simple influx, and if the proton gradient were toward the outside (i.e., pH, < pH 0 ), monovalent ionophores should cause shape change if they exchanged sodium for protons. Protons are present in such low concentration in the external medium that potassium exchange will predominate unless the external medium is alkaline. The monovalent ionophores, monensin and nigericin, do indeed cause platelet shape change in alkaline media (pH 8.2), but the rate is slower than the very rapid change seen after addition of ADP, serotonin, or thrombin. The effect is not due to serotonin or ADP released from the platelets. 134 Although sodium appears to play a role in platelet activation, perhaps via proton exchange, it is not a predominant role, since sodium removal does not affect primary aggregation or the effects of higher concentrations of thrombin. 128
Role of Cytoplasmlc Calcium
The calcium ionophore A23187 causes platelet shape change, aggregation, and secretion, responses essentially the same as those produced by thrombin. 135 -137 This supports the view that, as in other cells, ionized calcium is an important intracellular second messenger.
Platelet responses to A23187 and thrombin are well maintained in the absence of external calcium except for aggregation. Therefore, if cytoplasmic Ca 2+ increases, it must come from intraplatelet sources. Platelets contain a high concentration of calcium. About 60% is in the dense granules; this can be secreted into the medium but does not reach the cytoplasm. 138 The calcium concentration is very low in the cytoplasm (100 nM or less). 139 Some calcium may be associated with the plasma membrane, and the remainder of the functional platelet calcium is probably located in the dense tubular system, which is analogous to the sarcoplasmic reticulum in skeletal muscle. 137 Platelet vesicles that are presumably formed from the dense tubular system can concentrate calcium if ATP is present; 140 ' 141 some investigators find that cyclic AMP is also necessary. 140 Several compounds have been used to measure changes in the distribution or concentration of platelet calcium. Chlorotetracycline (CTC) is thought to detect calcium in membranes, because it localizes in areas of high lipid concentration, and fluoresces strongly when bound to calcium. 142 There is some question, however, about the parameter that it actually measures. 143 CTC fluorescence decreases when platelets are stimulated with ADP 142 or thrombin, 13 ' 144 suggesting that membrane calcium is released. With thrombin, the decrease is seen within 2 seconds, preceding secretion, and occurs without added external calcium. 13 Cytoplasmic calcium can be measured directly using quin 2, a compound whose fluorescence increases when it is complexed with calcium. 139 Quin 2 is added as an ester that readily penetrates cells; it is hydrolyzed intracellularly and binds calcium. Studies with quin 2 show that thrombin added in the presence of 1 mM external Ca 2+ causes cytoplasmic calcium to increase from an apparent basal level of less than 0.1 to 3 /xM. When [Ca 2+ ] 0 was only about 50 nm, thrombin caused shape change with little elevation of [Ca 2+ ],. 139 This suggests that an influx of Ca 2+ is responsible for the increase in [Ca 2+ ]j seen when the platelets are stimulated in medium containing Ca 2+ . However, studies with 45 Ca do not support this view. 76 When platelets containing quin 2 were stimulated with the calcium ionophore ionomycin in the presence of 1 mM [Ca 2+ ] 0 , the apparent threshold for [Ca 2+ ], necessary for shape change was lower than that for secretion, which in turn was lower than that for aggregation. 139 Inhibition caused by elevating cyclic AMP with PGE, causes loss of aggregability first. 152 TMB-6 (6-[N,N-diethylamino]octyl-3,4,5-trimethoxybenzoate), an intracellular calcium antagonist, blocks thrombin-induced secretion without affecting ADP-induced shape change and aggregation, 153 and metabolic inhibitors cause loss of secretory function first, then the ability to aggregate, and finally the ability to change shape. 154 Thus, shape change requires the least [Ca 2+ ]j and is the most difficult to inhibit, whereas the relative inhibition of aggregation and secretion varies with the conditions.
Changes In Inositol Phosphatldes
Alterations in phosphatidylinositides occur during stimulation of many types of cells including platelets.
The subject has been well reviewed. 155 -160 The sequence of events has been difficult to follow because compounds are resynthesized as well as degraded, and doubtless depends on the responsiveness of the platelet preparation. Recent studies focus on changes that occur within a few seconds.
Phosphatidylinositol-4,5-bisphosphate (PIP 2 ) and phosphatidylinositol-4-phosphate (PIP) form a small proportion of the phosphatidylinositol (PI) fraction of cells. Decreases in concentration 144 . 161 and radioactivity (^P-labeled) 161 ' 162 of PIP 2 occur less than 5 to 10 seconds after horse or human platelets have been stimulated with thrombin, and earlier than a change in PI. PIP 2 can bind divalent cations. If it bound only Ca 2+ , a drop in its concentration should release enough calcium to equal the increment of Ca 2+ detected in activated platelets. 144 ' 161 . 163 This is an unlikely source of Ca 2+ , however, since PIP 2 also binds Mg 2+ , which is present in the cytoplasm in far higher concentration than Ca 2+ (see reference 164) .
With rabbit platelets, ADP decreased PIP 2 concentration and increased its specific activity; 163 thrombin decreased both parameters. 165 It has been suggested that agonists cause PIP 2 to decrease because the ATP necessary to maintain its normal level is also decreased. 163 This view is supported by the observation that PGE, or PGI 2 reportedly causes shape change in rabbit platelets, perhaps by diverting ATP for use in forming cyclic AMP. 166 Most investigators, however, think that the decrease in PIP 2 occurring after platelet stimulation results from the phosphoesteratic activity of a phosphatidylinositide-specific phospholipase C, 163 ' 167 leading to the formation of DAG and inositol-1,4,5trisphosphate (IP 3 ) ( Figure 5 ). The enzyme is found in the cytoplasm even in activated platelets, 168 and requires Ca 2+ . Very likely the resting [Ca 2+ ]| is adequate for the enzyme to act, and stimulation may cause the substrate (PIP 2 ) to be translocated in the membrane so that it becomes accessible to the cytoplasmic enzyme. PMA, which simulates DAG (see PIP 2 Phospholipase C DAG + IP 3
4O-47K protein PS, Ca J + ,
Myosln light chain I Myosln light chain klnase
Myosln light chain I-P Figure 5 . Proposed sequence of reactions that follow the association of an agonist with its receptor on the platelet membrane. below), causes the enzyme to become associated with the plasma membrane. 169 The DAG formed from breakdown of PIP 2 (or PIP or PI) is rapidly phosphorylated to phosphatidic acid (PA). 156 ' 17° The formation of PA may be under separate control from PIP 2 breakdown since, unlike the breakdown of the phosphatidylinositols, it requires continued receptor occupancy by thrombin. 94 IP 3 , the other product of PIP 2 hydrolysis, has recently been shown to be a calcium ionophore. 171172 Lysophosphatidic acids, which are produced when arachidonic acid is liberated (see below), can also act as ionophores. 170 ' 173 These compounds could release cytoplasmic calcium from the dense tubular system. DAG is more than a byproduct of PIP 2 breakdown. Recent studies by Nishizuka's group 174175 have pointed to its role as a cofactor in the activation of protein kinase C. This kinase also requires calcium ions and phospholipid, usually phosphatidylserine. DAG lowers the concentration of Ca 2+ required by the enzyme, presumably to the level in platelet cytoplasm. The activated enzyme phosphorylates a protein with a molecular weight variously reported as 40,000 to 47,000. Phosphorylation is associated with secretion 174176177 but may also be produced with weak stimuli that do not cause secretion. The protein has been purified 178 but its mechanism of action is unknown.
Modified DAG (1-oleoyl-2-acetyl-glycerol or OAG) can penetrate cell membranes. It activates protein kinase C in vitro and also causes platelets to form the 40K phosphorylated protein and secrete serotonin.' 79 PMA can substitute for DAG in activating protein kinase C. 180 It induces slow progressive platelet aggregation and secretion. 181 
Interaction between Elevated Ca 2+ and Protein Kinase C
Increased Ca 2+ caused by calcium ionophores does not cause breakdown of PIP 2 161184 or phosphorylation of the 40 K protein, but does increase phosphorylation of myosin light chain I (20 K protein), 109 ' 183 which leads to shape change. If the ionophore A 23187 does cause production of DAG and PA and a decrease in PIP 2 , these changes can be abolished by NSAI agents plus enzymes that destroy ADP, indicating that they are secondary reactions to newly formed PGH/TxAj and secreted ADP. 184 In contrast, DAG, OAG, or PMA activates protein kinase C, leading to phosphorylation of the 40 K protein and secretion, with little phosphorylation of myosin light chain. 183185 The present consensus is that both the increase in cytoplasmic Ca 2+ and production of DAG by PIP 2 hydrolysis are essential for full activation. 155 ' 16 »' 18 3' 18 5 Another approach to studying the relative importance of [Ca 2+ ], has been use of platelets made permeable to ions by application of electric shocks. The [Ca 2+ ], can be set by suspending the platelets in buffers of known calcium ion concentration. 188 Secretion of 14 C-serotonin occurs with calcium alone with an ECgo of 2.0 fiM Ca 2+ . In the presence of thrombin, PMA or OAG, however, the EC^ for Ca 2+ is only 0.3 to 0.5 /xM, indicating a synergistic effect. 188187 Thrombin causes formation of DAG and phosphorylation of the 40-47 K portein and myosin light chain in permeabilized platelets, but the relationship of these changes to 14 C-serotonin secretion is complex. 187 Elevation of cyclic AMP inhibits thrombin-induced 14 C-serotonin secretion and phosphorylation of the 40 K protein in whole platelets. 185188 It also inhibits secretion in permeabikzed cells, where [Ca 2^, cannot be altered, 188 which indicates that the nucleotide acts not only by lowering cytoplasmic Ca 2+ . It has been reported that elevation of cyclic AMP does not affect the initial PIP 2 breakdown induced by thrombin 189 or PAF-acether, 190 although it inhibits the formation of PA and resynthesis of PIP 2 . 190 This suggests that resynthesis of PIP 2 (i.e., turnover) is important, a conclusion reached from studies in other tissues. 157 In contrast to cyclic AMP, which always inhibits platelet responses, cyclic 3', 5'-guanosine phosphate (GMP) has complex effects, being inhibitory in some studies 185 and excitatory in others. 188
Role of Arachldonlc Acid and Responses to Collagen
Arachidonic acid is found in the 2-position of platelet phospholipids, especially the phosphatidylinositides and phosphatidylethanolamine (PE). 191 ' 192 The free arachidonic acid necessary for TxAg synthesis is cleaved from PI, PE, and phosphatidylcholine (PC) by phospholipase A 2 193 which is activated by calcium. 158 ' 184 ' 194 There is some evidence that it is also cleaved from DAG by a diglyceride lipase. 195 Whereas thrombin, PAF-acether, and ADP exert their major effects directly, the effects of moderate amounts of collagen depend to a considerable extent on arachidonate metabolism. In a stirred system such as an aggregometer, inhibition of TxAj formation with NSAI prevents PA formation (a reflection of PIP 2 hydrolysis) as well as responses such as shape change and secretion. Thus, PIP 2 hydrolysis depends upon formation of endoperoxides and TxA^1 96 The direct responses of the platelets that adhere to collagen must be different, since degranulation (i.e., secretion) is not blocked by NSAI and is thus not dependent upon TxAj formation. 96103 Biochemical changes such as PIP 2 hydrolysis have not been studied under these conditions of high adherence with blocked TxA2 formation and blocked aggregation.
Effects of Aggregation
A number of effects reportedly occur only when platelets are aggregated, but not when they are acti-vated without coming into contact with one another. Among these aggregation-dependent effects are: secretion induced by ADP and epinephrine; 9596 increase in platelet cyclic GMP; 197 activation of the calcium-dependent protease; 80 rapid dephosphorylation of actin binding protein; 113 and possibly, inclusion of GP Mb and Ilia in the cytoskeleton (see above). Close platelet contact can also stimulate platelet metabolism. 198 ' 199 It will be of interest to determine the effects of aggregation on some more basic parameters such as PIP 2 breakdown or [Ca 2+ ]|.
Summary
Platelets are discoidal cytoplasmic particles that respond to a variety of stimuli by developing filopodia and rounding up (shape change), developing the ability to bind fibrinogen from the medium, and, with strong stimuli such as thrombin and PAF-acether, secreting the contents of several types of granules. Arachidonic acid is cleaved from phospholipids by phospholipase Aj and converted by the platelets to endoperoxides, and then to thromboxane A^,. The bound dimeric fibrinogen molecules probably cause aggregation by forming bridges between platelets. Aggregation is reinforced by secreted fibrinogen and thrombospondin, which binds the platelets, and by thromboxane Aj and endoperoxides, as well as secreted ADP, which cause additional receptor-mediated activation.
The responses to these stimuli are initiated when the agonists bind to specific receptors on the plasma membrane. Subsequent steps resemble those in other types of responsive cells: breakdown of phosphatidylinositol bisphosphate into diacylglycerol, a stimulator of protein kinase C, and inositol-1,4,5-trisphosphate, recently shown to be a potent calcium ionophore. The response of shape change results from increased cytoplasmic Ca 2+ which permits phosphorylation of one of the light chains of myosin by a calcium-calmodulin-dependent kinase, with resulting enhanced actin-myosin interaction. Secretion is associated with phosphorylation of a 40,000 to 47,000 dalton protein by the diacylglycerol-activated protein kinase C. These recent findings have increased our understanding of the mechanisms of platelet activation, but much remains to be learned. How do agonistreceptor complexes influence PIP 2 breakdown? Is this indeed the first step in activation? What mediates adhesion of platelets to the injured blood vessel wall? Does transduction of this stimulus occur by the same mechanism as transduction of commonly used soluble stimuli? What is the role of the phosphorylated 40-47 K protein in secretion? What change in GP llb-llla promotes their ability to bind fibrinogen? What is the role of calcium-activated protease? Of the phosphorylation of actin-binding protein? Progress is being made rapidly, and these questions may be answered within a few years.
